Rituximab in New Onset Type 1 Diabetes

NCT00279305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

87

Enrollment

NIH

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Anti-CD20 (rituximab)
DRUG: Placebo Comparator

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]